Get the Stockscreener App
7.06
5.23%
-0.39
After Hours:
7.06
Ocular Therapeutix Inc stock is traded at $7.06, with a volume of 1.19M.
It is down -5.23% in the last 24 hours and up +3.22% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$7.45
Open:
$7.46
24h Volume:
1.19M
Relative Volume:
0.78
Market Cap:
$1.40B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-5.2296
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
-19.77%
1M Performance:
+3.22%
6M Performance:
-36.40%
1Y Performance:
+20.89%
1-Day Range:
$7.02
$7.56
1-Week Range:
$6.84
$8.3339
52-Week Range:
$4.79
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.06 | 1.40B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com India
Bearish: Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Revenue and EPS estimates - simplywall.st
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers - Yahoo Finance
Analyst Expectations For Ocular Therapeutix's Future - Benzinga
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com Nigeria
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Raymond James maintains strong buy on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Ocular Therapeutix stock tumbles as Q1 results miss estimates By Investing.com - Investing.com Canada
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
OCUL's Financial Position: Cash Reserves Expected to Sustain Until 2028 | OCUL Stock News - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) Misses Estimate, Revenue Falls Short at $10.7 Million - GuruFocus
Ocular Therapeutix (OCUL) Advances Retinal Therapy Pipeline Amid Revenue Miss | OCUL Stock News - GuruFocus
Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls - marketscreener.com
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights | OCUL Stock News - GuruFocus
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights - The Manila Times
Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights - TradingView
BRIEF-Ocular Therapeutix Q1 EPS USD -0.38 Vs. IBES Estimate USD -0.29 - TradingView
Ocular Therapeutix Earnings: $349M War Chest Powers AXPAXLI Trials as FDA Backs NPDR Program - Stock Titan
Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Kn - GuruFocus
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Groundbreaking Retina Treatment Results Across 5 Major Healthcare Events - Stock Titan
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025 - GlobeNewswire
JPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Ocular Therapeutix Inc’s Market Journey: Closing Strong at 7.91, Up 3.94 - DWinneX
How To Trade (OCUL) - news.stocktradersdaily.com
Hydrogel-Based Drug Delivery System Market Detailed In New - openPR.com
Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24% - simplywall.st
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM - openPR.com
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listin - GuruFocus
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Hire: Ocular Therapeutix Strengthens Leadership with Key Payer Access Executive - Stock Titan
Key Trends Shaping the Future of Ocular Implants Market:Ocular Therapeutix Launches Clinical Trial For Axit... - WhaTech
William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - MSN
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Hypertension Pipeline Analysis and Clinical Trials - openPR.com
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts - Benzinga
William Blair starts Ocular Therapeutix stock with Outperform By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):